MYRIAD GENETICS INC (MYGN)
MYRIAD GENETICS INC (MYGN)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| (gain) loss on termination of lease | NaN | 0 | 0 | 0 |
| Net loss | -34,100 | -7,900 | -27,400 | -330,600 |
| Depreciation and amortization | 12,500 | 12,600 | 12,600 | 28,500 |
| Non-cash lease expense | 1,000 | 1,100 | 1,000 | 5,600 |
| Stock-based compensation expense | 6,500 | 2,800 | 12,200 | 20,200 |
| Deferred income taxes | NaN | 100 | 0 | 0 |
| Gain on acquisition | NaN | 0 | 0 | 0 |
| Unrecognized tax benefits | 0 | 64,000 | 0 | -31,500 |
| Impairment of goodwill and long-lived assets | 5,400 | 2,700 | 0 | 316,700 |
| Other non-cash adjustments | 1,200 | 1,800 | 1,300 | 300 |
| Prepaid expenses and other current assets | 9,700 | -3,300 | 3,400 | -300 |
| Trade accounts receivable | 8,700 | -2,600 | -19,000 | 15,400 |
| Inventory | -2,700 | -900 | 2,900 | 1,200 |
| Prepaid taxes | -10,000 | -1,800 | -500 | -2,100 |
| Other assets | 500 | -700 | -600 | -700 |
| Tenant improvement allowance received | NaN | 0 | NaN | NaN |
| Accounts payable | 5,400 | -4,200 | -800 | 3,600 |
| Accrued liabilities | -7,400 | -6,700 | 8,400 | -29,200 |
| Net cash used in operating activities | -15,700 | 10,600 | 21,100 | -29,900 |
| Proceeds from the sale of business, net cash sold | NaN | 0 | 0 | NaN |
| Proceeds from maturities and sales of marketable investment securities | NaN | 0 | 0 | 0 |
| Capital expenditures | 5,400 | 4,700 | 2,800 | 8,100 |
| Capitalization of intangible assets | 1,100 | 1,300 | 3,400 | 7,100 |
| Net cash used in investing activities | -6,500 | -6,000 | -6,200 | -15,200 |
| Proceeds from common stock issued under stock-based compensation plans | NaN | 600 | 0 | 2,700 |
| Payment of tax withheld for common stock issued under stock-based compensation plans | 2,900 | 1,200 | 300 | 5,800 |
| Proceeds from underwritten public offering, net of costs and discounts | NaN | 0 | NaN | NaN |
| Proceeds from revolving credit facility | 0 | 0 | 0 | 40,000 |
| Repayment of revolving credit facility | 0 | 0 | 60,000 | 20,500 |
| Proceeds from the issuance of secured long-term credit facility | NaN | 0 | 125,000 | NaN |
| Fees associated with issuance of secured long-term credit facility and refinancing of revolving credit facility-Secured Debt | NaN | 8,600 | NaN | NaN |
| Fees associated with issuance of secured long-term credit facility and refinancing of revolving credit facility-Revolving Credit Facility | NaN | 0 | NaN | NaN |
| Release of cash held in escrow | NaN | 7,500 | NaN | NaN |
| Fees associated with the issuance of secured long-term credit facility | NaN | NaN | 8,400 | NaN |
| Other financing activities | NaN | -200 | NaN | NaN |
| Payment on finance leases | -200 | NaN | 100 | 200 |
| Net cash (used in) provided by financing activities | -3,000 | -8,200 | 56,200 | 16,200 |
| Effect of foreign exchange rates on cash, cash equivalents, and restricted cash | -100 | 100 | 0 | 700 |
| Change in cash and cash equivalents classified as held for sale | NaN | NaN | NaN | 0 |
| Net decrease in cash, cash equivalents, and restricted cash | -25,300 | -3,500 | 71,100 | -28,200 |
| Cash, cash equivalents, and restricted cash at beginning of the period | 151,300 | 154,800 | 111,900 | NaN |
| Cash, cash equivalents, and restricted cash at end of the period | 126,000 | 151,300 | 154,800 | NaN |